Full Press Release Details
MINNEAPOLIS, Nov. 06, 2018 (GLOBE NEWSWIRE) -- DiaMedica Therapeutics Inc. (TSX-V:DMA) (OTCQB:DMCAF), a clinical stage biopharmaceutical company, today announced the voting results from its Annual General and Special Shareholders Meeting held on November 6, 2018. A total of 51.4% of the issued and outstanding common shares of the Company were present either in person or by proxy at the meeting.
The following five nominees proposed by the Company were elected as Directors of DiaMedica to serve until the Company’s next Annual General Meeting of Shareholders. The vote results were as follows:
| DIRECTOR | VOTES CAST FOR | % OF VOTES CAST FOR | WITHHELD | % WITHHELD |
| Dr. Michael Giuffre | 56,984,552 | 99.87% | 71,750 | 0.13% |
| James Parsons | 57,055,102 | 100% | 1,200 | 0% |
| Rick Pauls | 57,038,252 | 99.97% | 18,050 | 0.03% |
| Richard Pilnik | 57,045,102 | 99.98% | 11,200 | 0.02% |
| Zhenyu "Jerry" Xiao | 57,055,102 | 100% | 1,200 | 0% |
DiaMedica shareholders also approved all ballot resolutions, with a minimum of 95.5% of votes cast in favor of each resolution, placed before the meeting and as outlined in the Management Information Circular dated September 30, 2018. The Company’s Management Information Circular is available at www.sedar.com for more details on the matters covered at the meeting. Final voting results on all matters voted on at the meeting will also be filed on SEDAR.
About DiaMedica Therapeutics Inc.
For further information, please contact:
Vice President of Business Development
DiaMedica Therapeutics Inc.
Two Carlson Parkway, Suite 260
Phone: (617) 899-5941
Tags
Acute Ischemic Stroke
Chronic Kidney Disease